The effects of Efaproxyn™ (Efaproxiral) on subcutaneous RIF-1 tumor oxygenation and enhancement of radiotherapy-mediated inhibition of tumor growth in mice

Radiation Research

Volumn 168, Issue 2, 2007, Pages 218-225

  Hou, Huagang ^a   Khan, Nadeem ^a   Grinberg, Oleg Y ^a   Yu, Hongsheng ^a   Grinberg, Stalina A ^a   Lu, Shiyi ^a   Demidenko, Eugene ^a   Steffen, Robert P ^b   Swartz, Harold M ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b Allos Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAPROXIRAL; EFAPROXYN; UNCLASSIFIED DRUG; ANILINE DERIVATIVE; OXYGEN; PROPIONIC ACID DERIVATIVE; RADIOSENSITIZING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG INHIBITION; ELECTRON SPIN RESONANCE; FEMALE; FIBROSARCOMA; MOUSE; NONHUMAN; OXIMETRY; OXYGEN BREATHING; OXYGENATION; PRIORITY JOURNAL; RADIATION DOSE; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; C3H MOUSE; METABOLISM; PATHOLOGY; SKIN TUMOR; TUMOR CELL LINE;

MUS;

ANILINE COMPOUNDS; ANIMALS; CELL LINE, TUMOR; FEMALE; MICE; MICE, INBRED C3H; OXIMETRY; OXYGEN; PROPIONIC ACIDS; RADIATION-SENSITIZING AGENTS; SKIN NEOPLASMS;

EID: 34548452492     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR0962.1     Document Type: Article

References (40)

1. M. Hockel, K. Schlenger, B. Aral, M. Mitze, U. Schaffer and P. Vaupel, Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56, 4509-4515 (1996).
2. D. M. Brizel, S. P. Scully, J. M. Harrelson, L. J. Layfield, J. M. Bean, L. R. Prosnitz and M. W. Dewhirst, Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 56, 941-943 (1996).
3. M. Nordsmark, M. Overgaard and J. Overgaard, Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol. 41, 31-40 (1996).
4. A. W. Fyles, M. Milosevic, R. Wong, M. C. Kavanagh, M. Pintilie, A. Sun, W. Chapman, W. Levin, L. Manchul and R. P. Hill, Oxygenation predicts radiation response and survival in patients with cervical cancer. Radiother. Oncol. 48, 149-156 (1998).
5. P. Stadler, A. Becker, H. J. Feldmann, G. Hansgen, J. Dunst, F. Wurschmidt and M. Molls, Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 44, 749-754 (1999).
6. P. Vaupel. D. K. Kelleher and O. Thews, Modulation of tumor oxygenation. Int. J. Radiat. Oncol. Biol. Phys. 42, 843-848 (1998).
7. D. J. Abraham, R. A. Peascoe, R. S. Randad and J. Panikker, X-ray diffraction study of di- and tetra-ligated T-state hemoglobin from high salt crystals. J. Mol. Biol. 227, 480-492 (1992).
8. D. G. Hirst, P. J. Wood and H. C. Schwartz, The modification of hemoglobin affinity for oxygen and tumor radiosensitivity by antilipidemic drugs. Radiat. Res. 112, 164-172 (1987).
9. D. W. Siemann, K. L. Alliet and L. M. Macler, Manipulations in the oxygen transport capacity of blood as a means of sensitizing tumors to radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 16, 1169-1172 (1989).
10. S. R. Khandelwal, R. S. Randad, P. S. Lin, H. Meng, R. N. Pittman, H. A. Kontos, S. C. Choi, D. J. Abraham and R. Schmidt-Ullrich, Enhanced oxygenation in vivo by allosteric inhibitors of hemoglobin saturation. Am. J. Physiol. 265, H1450-H1453 (1993).
11. 2 (measured by EPR oximetry) following severe hemorrhagic shock in rats. Adv. Exp. Med. Biol. 530, 319-329 (2003).
12. O. Y. Grinberg, M. Miyake, H. Hou, R. P. Steffen and H. M. Swartz, The dose-dependent effect of RSR13, a synthetic allosteric modifier of hemoglobin, on physiological parameters and brain tissue oxygenation in rats. Adv. Exp. Med. Biol. 530, 287-296 (2003).
13. S. R. Khandelwal, P. S. Lin, C. E. Hall, Q. T. Truong, J. Lu, J. J. Laurent, G. S. Joshi, D. J. Abraham and R. K. Schmidt-Ullrich, Increased radiation response of FSaII fibrosarcomas in C3H mice following administration of an allosteric effector of hemoglobin-oxygen affinity. Radiat. Oncol. Invest. 4, 51-59 (1996).
14. B. A. Teicher, G. Ara, Y. Emi, Y. Kakeji, M. Ikebe, Y. Maehara and D. Buxton, RSR13: Effects on tumor oxygenation and response to therapy. Drug. Dev. Res. 38, 1-11 (1996).
15. G. P. Amorino, H. Lee, G. E. Holburn, C. B. Paschal, S. K. Hercules, Y. Shyr, R. P. Steffen and H. Choy, Enhancement of tumor oxygenation and radiation response by the allosteric effector of hemoglobin, RSR13. Radiat. Res. 156, 294-300 (2001).
16. S. Rockwell and M. Kelley, RSR13, a synthetic allosteric modifier of hemoglobin, as an adjunct to radiotherapy: Preliminary studies with EMT6 cells and tumors and normal tissue in mice. Radiat. Oncol. Invest. 6, 199-208 (1998).
17. B. A. Teicher, J. S. Wong, H. Takeuchi, L. M. Gravelin, G. Ara and D. Buxton, Allosteric effectors of hemoglobin as modulators of chemotherapy and radiation therapy in vitro and in vivo. Cancer Chemother. Pharmacol. 42, 24-30 (1998).
18. H. Hou, N. Khan, J. A. O'Hara, O. Y. Grinberg, J. F. Dunn, M. A. Abajian, C. M. Wilmot, M. Makki, E. Demidenko and H. M. Swartz, Effect of the allosteric hemoglobin modifier RSR13 on oxygenation in murine tumors: An in vivo EPR oximetry and BOLD MRI study. Int. J. Radiat. Oncol. Biol. Phys. 59, 834-843 (2004).
19. L. Kleinberg, S. A. Grossman, K. Carson, G. Lesser, A. O'Neill, J. Pearlman, P. Phillips, T. Herman and M. Gerber, Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study. J. Clin. Oncol. 20, 3149-3155 (2002).
20. E. Shaw, C. Scott, J. Suh, S. Kadish, B. Stea, J. Hackman, A. Pearlman, K. Murray, L. Gaspar and M. Gerber, RSR13 plus cranial radiation therapy in patients with brain metastases: Comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database. J. Clin. Oncol. 21, 2364-2371 (2003).
21. H. Choy, A. Nabid, B. Stea, C. Scott, W. Roa, L. Kleinberg, J. Ayoub, C. Smith, L. Souhami and W. J. Curran, Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer. J. Clin. Oncol. 23, 5918-5928 (2005).
22. J. H. Suh, B. Stea, A. Nabid, J. J. Kresl, A. Fortin, J. P. Mercier, N. Senzer, E. L. Chang, A. P. Boyd and E. Shaw, Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J. Clin. Oncol. 24, 106-114 (2006).
23. H. Hou, N. Khan, J. A. O'Hara, O. Y. Grinberg, J. F. Dunn, M. A. Abajian, C. M. Wilmot, E. Demidenko, S. Lu and H. M. Swartz, Increased oxygenation of intracranial tumors by RSR13, an allosteric hemoglobin modifier: In vivo EPR oximetry study. Int. J. Radiat. Oncol. Biol. Phys. 61, 1503-1509 (2005).
24. K. J. Liu, P. Gast, M. Moussavi, S. W. Norby, N. Vahidi, T. Walczak, M. Wu and H. M. Swartz, Lithium phthalocyanine: A probe for electron paramagnetic resonance oximetry in viable biological systems. Proc. Natl. Acad. Sci. USA 90, 5438-5442 (1993).
25. H. Hou, O. Y. Grinberg, S. A. Grinberg, E. Demidenko and H. M. Swartz, Cerebral tissue oxygenation in reversible focal ischemia in rats: Multi-site EPR oximetry measurements. Physiol. Meas. 26, 131-141 (2005).
26. H. M. Swartz and T. Walczak, Developing in vivo EPR oximetry for clinical use. Adv. Exp. Med. Biol. 454, 243-252 (1998).
27. H. Hirata, T. Walczak and H. M. Swartz, Electronically tunable surface-coil-type resonator for L-band EPR spectroscopy. J. Magn. Reson. 142, 159-167 (2000).
28. A. I. Smirnov, S. W. Norby and R. B. Clarkson, Simultaneous multisite EPR spectroscopy in vivo. Magn. Reson. Med. 30, 213-220 (1993).
29. E. Demidenko and T. Stukel, Efficient estimation of general mixed effects models. J. Stat. Plan. Infer. 104, 197-219 (2002).
30. E. Demidenko, Mixed Models: Theory and Applications. Wiley, New York, 2004.
31. G. Ilangovan, H. Li, J. L. Zweier, M. C. Krishna, J. B. Mitchell and P. Kuppusamy, In vivo measurement of regional oxygenation and imaging of redox status in RIF-1 murine tumor: Effect of carbogen-breathing. Magn. Reson. Med. 48, 723-730 (2002).
32. E. J. Hall, Radiobiology for the Radiologist, 5th ed., pp. 91-111. Lippincott Williams & Wilkins, Philadelphia, 2000.
33. S. R. Khandelwal, B. D. Kavanagh, P. S. Lin, Q. T. Truong, J. Lu, D. J. Abraham and R. K. Schmidt-Ullrich, RSR13, an allosteric effector of haemoglobin, and carbogen radiosensitize FSAII and SCCVII tumours in C3H mice. Br. J. Cancer 79, 814-820 (1999).
34. 3H misonidazole binding and paired survival assay. Radiat. Res. 145, 491-500 (1996).
35. F. Goda, J. A. O'Hara, E. S. Rhodes, K. J. Liu, J. F. Dunn, G. Bacic and H. M. Swartz, Changes of oxygen tension in experimental tumors after a single dose of X-ray irradiation. Cancer Res. 55, 2249-2252 (1995).
36. B. W. Pogue, J. A. O'Hara, C. M. Wilmot, K. D. Paulsen and H. M. Swartz, Estimation of oxygen distribution in Rif-1 tumors by diffusion model-based interpretation of pimonidazole hypoxia and Eppendorf measurements. Radiat. Res. 155, 15-25 (2001).
37. 2 measurements by electron paramagnetic resonance oximetry. Radiat. Res. 150, 549-556 (1998).
38. C. A. Znati, M. Rosenstein, Y. Boucher, M. W. Epperly, W. D. Bloomer and R. K. Jain, Effect of radiation on interstitial fluid pressure and oxygenation in a human tumor xenograft. Cancer Res. 56, 964-968 (1996).
39. H. M. Swartz and R. B. Clarkson, The measurement of oxygen in vivo using EPR techniques. Phys. Med. Biol. 43, 1957-1975 (1998).
40. H. M. Swartz, J. Buckey, R. Comi, L. Could, O. Y. Grinberg, A. Hartford, H. Hopf, H. Hou, E. Hug and T. Walczak, Clinical application of EPR: Overview & perspectives. NMR Biomed. 17, 335-351 (2004).